IVD & LDT For Autoimmune Diseases Market - Global Forecast 2025-2032

The IVD & LDT For Autoimmune Diseases Market continues to evolve rapidly, supported by breakthrough diagnostic technologies, shifting regulatory landscapes, and increasing demand for personalized patient care.

Market Snapshot: Solid Growth for IVD & LDT in Autoimmune Disease Testing

This market report presents a detailed assessment of the IVD & LDT for Autoimmune Diseases Market, which expanded from USD 18.30 billion in 2024 to USD 19.26 billion in 2025, with projections indicating growth at a 5.25% CAGR to USD 27.56 billion by 2032. The analysis covers comprehensive market dynamics, identifying emerging trends, evolving stakeholder needs, and the impact of technological advancements and regulatory changes on global autoimmune diagnostic solutions.

Scope & Segmentation of the IVD & LDT For Autoimmune Diseases Market

• Test Types: Anti Cyclic Citrullinated Peptide, Antinuclear Antibody, Celiac Disease, Rheumatoid Factor
• Technology: Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Fluorescence Immunoassay, Multiplex Immunoassay
• Product Types: In Vitro Diagnostic, Lab Developed Test
• End Users: Academic and Research Institutes, Diagnostic Laboratories, Hospital Laboratories, Reference Laboratories
• Applications: Celiac Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes
• Sample Types: Dried Blood Spot, Plasma, Serum, Whole Blood
• Regions: Americas (including North America, Latin America), Europe, Middle East & Africa, Asia-Pacific. Sub-regional insights feature the United States, Canada, Brazil, United Kingdom, Germany, France, United Arab Emirates, South Africa, China, India, Japan, Australia, and more.
• Leading Companies: Roche Diagnostics International AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Siemens Healthineers AG, bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Quidel Corporation, EUROIMMUN AG

Key Takeaways: Strategic Insights into the Autoimmune Diagnostics Market

• Novel antigen detection and advanced analytical validation are increasing earlier and more accurate detection of autoimmune diseases, meeting the growing needs of diverse and complex patient populations.
• Balancing high-throughput efficiency with diagnostic precision, antibody panels like anti cyclic citrullinated peptide and antinuclear antibody assays are at the forefront of routine screening and early intervention.
• Lab-developed tests (LDTs) allow clinical laboratories to address niche and emerging biomarker needs, adapting protocols for specific disease subtypes or rare indications.
• Regulatory harmonization efforts are standardizing validation and quality control, improving assay consistency, and enabling manufacturers to bring innovative solutions to market more efficiently.
• Multiplex immunoassays and dried blood spot collection methods are expanding diagnostic reach, especially in resource-limited or remote settings, and are reshaping chronic disease management strategies.
• Strategic alliances between diagnostic companies, academia, and pharmaceutical firms accelerate integrated companion diagnostic development and support robust clinical decision-making in autoimmune therapy selection.

Tariff Impact: Navigating Evolving US Trade Policy

Upcoming US tariff policies for 2025 are set to increase procurement and logistics costs for imported reagents and equipment across the autoimmune disease testing supply chain. Direct cost pressures will encourage laboratories and manufacturers to review supplier agreements and explore alternative sourcing, toll manufacturing, and local assembly. Procurement teams are advised to conduct risk assessments and maintain resilient sourcing channels to sustain uninterrupted diagnostic services amid regulatory and trade uncertainties.

Methodology & Data Sources Supporting Market Intelligence

Insights derive from a multi-stage research approach combining exhaustive secondary data review—including regulatory, scientific, and industry reports—with primary interviews of lab directors, regulatory experts, and procurement specialists. Statistical analysis and stakeholder validation ensure that market trends and performance data are reliable and grounded. All information adheres to strict confidentiality and ethical data handling standards.

Why This Report Matters

• Empowers senior leaders with data-driven insights to optimize product portfolios, sourcing strategies, and market positioning.
• Enables effective risk management and capital allocation by clarifying technology adoption paths and anticipated regulatory changes.
• Facilitates informed decision-making for partnerships, investment in new assay development, and regional expansion.

Conclusion: Strategic Outlook for Sustainable Growth

The IVD & LDT for Autoimmune Diseases Market is positioned for continued advancement through technology-driven innovation, strengthened regulatory alignment, and patient-centric diagnostic strategies. Senior decision-makers can leverage these insights to shape long-term organizational success and market leadership.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.